MERTK and triple-negative breast carcinoma: Kasikara and coworkers showed that a pan-TAM (Tyro3, Axl, and Mertk) tyrosine kinase inhibitor enhanced the efficacy of anti-PD-1 antibody treatment in a murine model of triple negative breast cancer [24].